Table 2 The clinicopathological characteristics related to the expression of MFI2 in 115 samples of OSCC
Patient categories | Case number | MFI2 expression level | Â | |
|---|---|---|---|---|
Low (%) | High (%) | p value | ||
Sex | ||||
 Male | 103 | 56 (54.4) | 47 (45.6) | 0.404 |
 Female | 12 | 5 (41.7) | 7 (58.3) |  |
Agea |  | 51.0 ± 10.8 (78.3, 22.5) | 52.8 ± 13.4 (79.8, 20.3) | 0.550 |
Tumor classification | ||||
 T1–T2 | 58 | 32 (55.2) | 26 (44.8) | 0.644 |
 T3–T4 | 57 | 29 (50.9) | 28 (49.1) |  |
Node classification | ||||
 0 | 55 | 36 (65.5) | 19 (34.5) | 0.011b |
 > 0 | 60 | 25 (41.7) | 35 (58.3) |  |
Overall TNM stage | ||||
 I–II | 34 | 24 (70.6) | 10 (29.4) | 0.015b |
 III–IV | 81 | 37 (45.7) | 44 (54.3) |  |
ENE | ||||
 No | 84 | 48 (57.1) | 36 (42.9) | 0.147 |
 Yes | 31 | 13 (41.9) | 18 (58.1) |  |
PNI | ||||
 No | 59 | 38 (64.4) | 21 (35.6) | 0.012b |
 Yes | 56 | 23 (41.1) | 33 (58.9) |  |
Differentiation | ||||
 Well + moderately | 100 | 56 (56.0) | 44 (44.0) | 0.101 |
 Poorly | 15 | 5 (33.3) | 10 (66.7) |  |
Tumor depth (mm) | ||||
 ≤ 8 | 44 | 24 (54.5) | 20 (45.5) | 0.799 |
 > 8 | 71 | 37 (52.1) | 34 (47.9) |  |